CenterBook Partners LP Sells 7,784 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CenterBook Partners LP cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 32.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,984 shares of the biopharmaceutical company’s stock after selling 7,784 shares during the quarter. Regeneron Pharmaceuticals makes up 0.7% of CenterBook Partners LP’s holdings, making the stock its 29th biggest holding. CenterBook Partners LP’s holdings in Regeneron Pharmaceuticals were worth $11,386,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $802,036,000. Amundi grew its stake in shares of Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after buying an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock worth $1,122,168,000 after buying an additional 393,997 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% during the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after buying an additional 219,162 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after acquiring an additional 155,369 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $556.81 on Wednesday. The stock has a market cap of $60.87 billion, a P/E ratio of 14.55, a P/E/G ratio of 2.34 and a beta of 0.44. The business’s fifty day moving average is $669.26 and its 200 day moving average is $766.90. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $536.23 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.